The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.
Open accessAbstract
The ability of noncytolytic Lyt-1+,2- T cells immune to FBL-3 leukemia to effect eradication of disseminated FBL-3 was studied. Adult thymectomized, irradiated, and T-depleted bone marrow-reconstituted (ATXBM) B6 hosts were cured of disseminated FBL-3 by treatment with 180 mg/kg cyclophosphamide (CY) and adoptively transferred Lyt-1+,2- T cells obtained from congenic B6/Thy-1.1 donors immune to FBL-3. Analysis of the T cell compartment of ATXBM hosts treated and rendered tumor-free by this therapy revealed that the only T cells present in the mice were donor-derived Lyt-1+,2- T cells. In vitro stimulation of these T cells with FBL-3 tumor cells, which express class I but no class II major histocompatibility complex antigens, induced lymphokine secretion, but did not result in the generation of cytotoxic T lymphocytes (CTL). Thus, in a setting in which mice lack Lyt-2+ T cells, and in which no CTL of either host or donor origin could be detected, immune Lyt-1+,2- T cells, in conjunction with CY, mediated eradication of a disseminated leukemia. The results suggest that delayed-type hypersensitivity responses induced by immune T cells represent a potentially useful effector mechanism for in vivo elimination of disseminated tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity
Gillis, S., Ferm, M. M., Ou, W., & Smith, K. A. (1978) · The Journal of Immunology · doi:10.4049/jimmunol.120.6.2027 · Cited by 3,273
North, R. J. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.1063 · Cited by 650
Berendt, M. J., & North, R. J. (1980) · The Journal of experimental medicine · doi:10.1084/jem.151.1.69 · Cited by 369
Subversion of immune system by tumor cells and role of prostaglandins.
Plescia, O. J., Smith, A. H., & Grinwich, K. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1848 · Cited by 352
Greenberg, P. D., Cheever, M. A., & Fefer, A. (1981) · The Journal of experimental medicine · doi:10.1084/jem.154.3.952 · Cited by 312
Self-citationNorth, R. J., & Bursuker, I. (1984) · The Journal of experimental medicine · doi:10.1084/jem.159.5.1295 · Cited by 253
Wong, G. H. W., Clark-Lewis, I., McKimm-Breschkin, J. L., Harris, A. W., & Schrader, J. W. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.2.788 · Cited by 229
Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon.
King, D. P., & Jones, P. P. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.1.315 · Cited by 226
Abnormal migration of T lymphocyte clones.
Dailey, M. O., Fathman, C. G., Butcher, E. C., et al. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.128.5.2134 · Cited by 151
Kelso, A., Glasebrook, A. L., Kanagawa, O., & BRUNNER, K. T. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.2.550 · Cited by 141
Mills, C. D., & North, R. J. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.157.5.1448 · Cited by 122
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
Cheever, M. A., Greenberg, P. D., & Fefer, A. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.2.711 · Cited by 118
Self-citationInterleukin 2 administered in vivo induces the growth of cultured T cells in vivo.
Cheever, M. A., Greenberg, P. D., Irlé, C., et al. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.5.2259 · Cited by 104
Self-citationFernández‐Cruz, E., Halliburton, B. L., & Feldman, J. D. (1979) · The Journal of Immunology · doi:10.4049/jimmunol.123.4.1772 · Cited by 62
Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone.
Dailey, M. O., Pillemer, E., & Weissman, I. L. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.17.5384 · Cited by 62
Wilde, D. B., & Fitch, F. W. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.4.1632 · Cited by 52
Rosenstein, M., & Rosenberg, S. A. (1984) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/72.5.1161 · Cited by 34
Cited by
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898
Tumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 845
Metadata
- Authors
- Greenberg, P. D., Kern, D. E., & Cheever, M. A.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1985-05-01
- Volume
- 161
- Issue
- 5
- Pages
- 1122-1134
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2116236834
- Cited by
- 292
- References
- 17
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.